...
首页> 外文期刊>Journal of the American Medical Directors Association >Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial.
【24h】

Efficacy of oral extended-release oxybutynin in cognitively impaired older nursing home residents with urge urinary incontinence: a randomized placebo-controlled trial.

机译:口服奥昔布宁缓释片对认知功能障碍的老年护理院居民急迫性尿失禁的疗效:一项随机安慰剂对照试验。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: To determine the efficacy of oral extended-release oxybutynin for urge urinary incontinence in older female nursing home residents with mild to severe cognitive impairment. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: Twelve skilled nursing homes. PARTICIPANTS: Fifty women aged 65 and older with urge incontinence and cognitive impairment. INTERVENTION: Four-week treatment with daily oral extended-release oxybutynin 5 mg or placebo. MEASUREMENTS: Urinary incontinence episodes, urinary frequency, and total dryness assessed hourly over two 8-hour days (8 AM TO 4 PM), and evening and night nursing staff ratings of urinary symptoms. RESULTS: Of the participants, 96% (n = 25) on oxybutynin and 92% (n = 22) on placebo completed the trial. Compared with baseline, both groups achieved a significant median decrease in mean urinary incontinence episodes and urinary frequency at 4 weeks (P = .01-.05). There were no significant between-group differences in any urological outcome. In the exploratory analysis, there were no significant differences from baseline or placebo in any urological outcome with oxybutynin in participants with mild to moderate cognitive impairment and/or adequate mobility compared with participants with more severe cognitive and physical impairment. Staff ratings found that more participants had improvement in urinary symptoms from baseline with oxybutynin than placebo but significant only for delaying evening voiding (P = .02). CONCLUSION: Extended-release oxybutynin 5 mg per day for 4 weeks in older cognitively impaired female nursing home residents did not significantly reduce urinary incontinence and urinary frequency or achieve dryness. Participants with mild to moderate cognitive and/or physical impairment were no more likely to benefit from oxybutynin than more severely impaired individuals in an exploratory analysis but further research in a larger population and perhaps using a larger dose is needed.
机译:目的:确定口服缓释奥昔布宁对轻度至重度认知障碍的老年女性疗养院居民尿急的疗效。设计:随机,双盲,安慰剂对照试验。地点:十二个熟练的疗养院。参与者:五十名年龄在65岁及以上的女性,患有急迫性尿失禁和认知障碍。干预:每天口服奥昔布宁5 mg或安慰剂四周治疗。测量:在两个8小时的工作日(上午8点至下午4点)中每小时进行一次尿失禁发作,尿频和总干燥度的评估,以及夜间和夜间护理人员对尿液症状的评估。结果:参与者中,奥昔布宁96%(n = 25)和安慰剂92%(n = 22)完成了试验。与基线相比,两组在4周时的平均尿失禁发作和尿频均显着下降(P = 0.01-.05)。任何泌尿外科结果均无明显的组间差异。在探索性分析中,与轻度至中度认知障碍和/或适当活动能力较弱的参与者相比,奥昔布宁在任何泌尿外科泌尿外科结果中与基线或安慰剂无显着差异。员工评级发现,与奥昔布宁相比,使用奥昔布宁治疗的泌尿系统症状基线改善的患者多于安慰剂,但仅对延迟夜间排尿有效(P = .02)。结论:老年认知障碍女性疗养院居民每天服用奥昔布宁5 mg持续4周,并没有显着降低尿失禁和尿频或达到干燥状态。在探索性分析中,轻度至中度认知和/或身体障碍的参与者比重度障碍者更不可能从奥昔布宁中受益,但需要在更大的人群中进行进一步研究,也许需要使用更大剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号